NEW YORK (GenomeWeb) – BioTime subsidiary OncoCyte has entered into a deal with Cornell University to collaborate on developing a lung cancer diagnostic test, the parties announced today.

As part of the deal, Weill Cornell Medical College will provide blood samples derived from healthy patients and lung cancer patients. OncoCyte researchers will then use the firm's PanC-Dx diagnostic tests to analyze the samples to determine levels of tumor-associated gene expression, including levels of the company's proprietary PanC-Dx cancer biomarkers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers examine the gap in funding between researchers and research institutions, ScienceInsider reports

By sequencing two ancient dog genomes, researchers from the US and Germany suggest that dogs were domesticated in a single event, the Washington Post reports.

In Genome Research this week: population dynamics of E. coli infection, lncRNA expression changes in macaque aging, and more.

Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.